Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1276507

C=CCOC(=O)CC[C@H](NC(=O)NC(CCCCN)C(=O)OCC=C)C(=O)OCC=C.O=C(O)C(F)(F)F

nearest known ligand 0.45

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.35
TSHR P16473 1/20 0.34
KMT2A Q03164 2/20 0.34
POLB P06746 1/20 0.34
CASP1 P29466 2/20 0.34
CA12 O43570 2/20 0.33
CA1 P00915 2/20 0.33
CA9 Q16790 2/20 0.33
CA2 P00918 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CPB2 Q96IY4 3/20 0.32
SLC6A5 Q9Y345 1/20 0.31
ALDH1A1 P00352 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13400056 0.92 FOLH1 (0.49) FOLH1SMN1; SMN2TSHRKMT2APOLB
SCHEMBL13400091 0.92 FOLH1 (0.49) FOLH1SMN1; SMN2TSHRKMT2APOLB
SCHEMBL2742777 0.92 FOLH1 (0.49) FOLH1SMN1; SMN2TSHRKMT2APOLB
SCHEMBL14048647 0.90 FOLH1 (0.58) FOLH1TSHRCPB2SLC6A5
SCHEMBL14048625 0.86 FOLH1 (0.44) FOLH1SMN1; SMN2TSHRKMT2APOLB
SCHEMBL21943867 0.86 KMT2A (0.49) FOLH1SMN1; SMN2TSHRKMT2APOLB
SCHEMBL19594663 0.86 KMT2A (0.49) FOLH1SMN1; SMN2TSHRKMT2APOLB
SCHEMBL21844220 0.85 KMT2A (0.50) FOLH1SMN1; SMN2TSHRKMT2APOLB
SCHEMBL13515320 0.84 FOLH1 (0.42) FOLH1SMN1; SMN2TSHRKMT2APOLB
SCHEMBL11959174 0.82 SMN1; SMN2 (0.40) FOLH1SMN1; SMN2TSHRKMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2285350-B1 METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC NANOPARTICLES PFIZER (US) 2017-11-15 EP disclosed
US-8734846-B2 Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic targeted nanoparticles BIND BIOSCIENCES, INC. (US) 2014-05-27 US disclosed
US-20130115192-A1 Methods for the Preparation of Targeting Agent Functionalized Diblock Copolymers for Use in Fabrication of Therapeutic Targeted Nanoparticles BIND BIOSCIENCES, INC (US) 2013-05-09 US disclosed
EP-2285350-A2 METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC TARGETED NANOPARTICLES Bind Biosciences, Inc. (US) 2011-02-23 EP disclosed
US-20100104645-A1 METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC TARGETED NANOPARTICLES BIND BIOSCIENCES, INC. (US) 2010-04-29 US disclosed
WO-2010005740-A2 METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC TARGETED NANOPARTICLES BIND BIOSCIENCES, INC. (US) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130115192-A1 Methods for the Preparation of Targeting Agent Functionalized Diblock Copolymers for Use in Fabrication of Therapeutic Targeted Nanoparticles GNE, PAM, EPHA2 FOLH1 727/4885SMN1; SMN2 2165/4885TSHR 1807/4885
US-20100104645-A1 METHODS FOR THE PREPARATION OF TARGETING AGENT FUNCTIONALIZED DIBLOCK COPOLYMERS FOR USE IN FABRICATION OF THERAPEUTIC TARGETED NANOPARTICLES GNE, EPHA2, PAM FOLH1 1373/4885SMN1; SMN2 1667/4885TSHR 1745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.